Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1
NCT00795444
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- After receiving information on the design and objectives of the study, the possible risks involved, and the fact that they can refuse to collaborate at any time, patients will give their informed consent to participate in the study and agree to provide material for the cellular and molecular studies.
- Aged over 18 years.
- Chronic HIV infection
- Antiretroviral therapy with at least 3 drugs for at least 2 years and with no modifications expected during the study. Antiretroviral drugs can be switched due to intolerance as long as plasma viremia remains controlled.
- Undetectable viral load determined by ultrasensitive techniques (<50 copies HIV RNA/mL) for at least 2 years.
- CD4+ T lymphocyte count above 350 cells/mm3.
- Demonstration of R5 viral tropism (use of CCR5 coreceptors) by phenotyping in plasma samples stored before antiretroviral therapy is started.
- Understand the objective of the study and be available to make frequent visits to the hospital.
- Previous failure of antiretroviral therapy, understood as a rebound in viral load that
can be detected after having reached undetectable levels. Low-grade increases (<200
copies of HIV RNA/mL) and transitory increases (blips) resolved without modifying
antiretroviral therapy are excluded.
- Proven resistance against the antiretroviral drugs under study.
- Planned interruption of antiretroviral therapy.
- Taking immunosuppressive or immunostimulating medication of any type, including
valproic acid.
- Taking a fusion inhibitor (enfuvirtide).
- Pregnancy or intention to become pregnant during the study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Madrid,
- Birmingham, Alabama
- Hobson City, Alabama
- Hayward, California
- Los Angeles, California
- Los Angeles, California
- Newport Beach, California
- Palm Springs, California
- Sacramento, California
- Sacramento, California
- Sacramento, California
- San Francisco, California
- San Francisco, California
- San Francisco, California
- Santa Clara, California
- Union City, California
- Aurora, Colorado
- Denver, Colorado
- New Haven, Connecticut
- New Haven, Connecticut
- Norwalk, Connecticut
- Washington, District of Columbia
- Washington, District of Columbia
- Fort Lauderdale, Florida
- Fort Lauderdale, Florida
- Miami Beach, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Pensacola, Florida
- Tampa, Florida
- Tampa, Florida
- Tampa, Florida
- Tampa, Florida
- Tampa, Florida
- Wilton Manors, Florida
- Atlanta, Georgia
- Decatur, Georgia
- Decatur, Georgia
- Chicago, Illinois
- Chicago, Illinois
- Chicago, Illinois
- Iowa City, Iowa
- New Orleans, Louisiana
- New Orleans, Louisiana
- Springfield, Massachusetts
- Berkley, Michigan
- Detroit, Michigan
- Detroit, Michigan
- Detroit, Michigan
- East Lansing, Michigan
- East Lansing, Michigan
- Lansing, Michigan
- Minneapolis, Minnesota
- Kansas City, Missouri
- Omaha, Nebraska
- Neptune, New Jersey
- Neptune, New Jersey
- Neptune, New Jersey
- Newark, New Jersey
- Buffalo, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- Rochester, New York
- Valhalla, New York
- Charlotte, North Carolina
- Greenville, North Carolina
- Greenville, North Carolina
- Cincinnati, Ohio
- Toledo, Ohio
- Austin, Texas
- Dallas, Texas
- Dallas, Texas
- Dallas, Texas
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Seattle, Washington
- Seattle, Washington
- Darlinghurst, New South Wales
- Darlinghurst, New South Wales
- Darlinghurst, New South Wales
- Surry Hills, New South Wales
- Brisbane, Queensland
- Carlton, Victoria
- Melbourne, Victoria
- Wien,
- Antwerpen,
- Brussels,
- Brussels,
- Bruxelles,
- Gent,
- Liege,
- Vancouver, British Columbia
- Ottawa, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Hvidovre,
- Koebenhavn OE,
- Odense,
- Helsinki,
- Orleans, Cedex 02
- Paris, Cedex 12
- Paris, Cedex 18
- Bordeaux cedex,
- Creteil,
- Le Kremlin Bicetre,
- LYON Cedex 4,
- Montpellier,
- Nantes,
- Paris Cedex 10,
- Paris,
- Paris,
- Strasbourg Cedex,
- Tourcoing,
- Berlin,
- Berlin,
- Berlin,
- Bonn,
- Frankfurt am Main,
- Frankfurt am Main,
- Hamburg,
- Hamburg,
- Hamburg,
- Koeln,
- Muenchen,
- Muenchen,
- Budapest,
- Milano,
- Utrecht,
- Bydgoszcz,
- Warszawa,
- Wroclaw,
- Amadora,
- Lisboa,
- Lisboa,
- Porto,
- Bayamon,
- Ponce,
- Rio Piedras,
- Rio Piedras,
- San Juan,
- San Juan,
- L´hospitalet de Llobregat, Barcelona
- Alicante,
- Barcelona,
- Barcelona,
- Barcelona,
- Cordoba,
- Madrid,
- Madrid,
- Sevilla,
- Goteborg,
- Malmo,
- Stockholm,
- Stockholm,
- Basel,
- Bern,
- St. Gallen,
- Zurich,
- Birmingham,
- Brighton,
- Edinburgh,
- London,
- London,
- London,
- London,
- London,
- Manchester,
- Birmingham, Alabama
- Birmingham, Alabama
- Beverly Hills, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Newport Beach, California
- Oakland, California
- Sacramento, California
- San Francisco, California
- San Francisco, California
- Aurora, Colorado
- Jacksonville, Florida
- Miami Beach, Florida
- Miami, Florida
- Miami, Florida
- Orlando, Florida
- Sarasota, Florida
- Tampa, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Indianapolis, Indiana
- Baltimore, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Springfield, Massachusetts
- Omaha, Nebraska
- Albany, New York
- Brooklyn, New York
- Flushing, New York
- Manhasset, New York
- New York, New York
- Huntersville, North Carolina
- Cincinnati, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Philadelphia, Pennsylvania
- Columbia, South Carolina
- Dallas, Texas
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- Annandale, Virginia
- Puyallup, Washington
- Tacoma, Washington
- El Palomar, Provincia de Buenos Aires
- Neuquen, Provincia de Neuquen
- Buenos Aires,
- Ciudad de Buenos Aires,
- Ciudad de Buenos Aires,
- Ciudad de Buenos,
- Provincia de Buenos Aires,
- Provincia de Santa Fe,
- Burwood, New South Wales
- Darlinghurst, New South Wales
- Surrey Hills, New South Wales
- Wentworthville, New South Wales
- Herston, Queensland
- Miami, Queensland
- Melbourne, Victoria
- North Fitzroy, Victoria
- South Yarra, Victoria
- Brussels,
- Brussels,
- Gent,
- Leuven,
- Rio de Janeiro, RJ
- Calgary, Alberta
- Edmonton, Alberta
- Edmonton, Alberta
- Vancouver, British Columbia
- Vancouver, British Columbia
- Vancouver, British Columbia
- Vancouver, British Columbia
- Winnipeg, Manitoba
- Halifax, Nova Scotia
- Hamilton, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Sainte-Foy, Quebec
- Antella (FI),
- Brescia,
- Milano,
- Modena,
- Roma,
- Roma,
- Torino,
- Del. Tlalpan C.P., Mexico City
- Del. Tlalpan, C.P., Mexico D.F.
- Del. Tlalpan, C.P., Mexico D.F.
- Delegacion Tlalpan C. P, Mexico D.F.
- Amsterdam,
- Rotterdam,
- Utrecht,
- Bialystok,
- Bydgoszcz,
- Chorzow,
- Gdansk,
- Krakow,
- Szczecin,
- Warszawa,
- Ponce,
- Rio Piedras,
- San Juan,
- San Juan,
- Port Elizabeth, Eastern Cape
- Bloemfontein, Free State
- Johannesburg, Gauteng
- Pretoria, Gauteng
- Dundee, KwaZulu Natal
- Bloomfontein,
- Cape Town,
- Cape Town,
- Cape Town,
- Cape Town,
- Johannesburg,
- Pretoria North,
- Pretoria,
- Soweto, Johannesburg,
- Basel,
- Bern,
- Genève,
- Lugano,
- St. Gallen,
- Zürich,
- Zürich,
- Edinburgh, Loth
- Birmingham,
- Brighton,
- Edinburgh,
- London,
- London,
- London,
- London,
- Manchester,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 | |||
Official Title ICMJE | Pilot Study Of The Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 In Patients Taking Highly Active Antiretroviral Therapy | |||
Brief Summary | The presence of a pool of cells latently infected by HIV-1 in patients taking HAART and with a viral load below 50 copies/mL is the main limitation to eradication of the virus from the body. This viral reservoir prevents antiretroviral therapy from being interrupted; therefore, patients are obliged to continue with treatment for a period calculated to be greater than 60 years. Despite the important advances in knowledge of the biology of this reservoir, we still have no real knowledge about its dynamics. The opportunity to carry out a clinical trial for the first time with CCR5 coreceptor antagonists is exceptional, since the results could provide important information on the nature of this reservoir. If maintenance of the reservoir is a dynamic process, inclusion of CCR5 inhibitors is expected to lead to a reduction in the size of this reservoir. This effect could be critical when including IAT (viral reactivation), since, in theory, it would be necessary to act on a smaller reservoir. Current consensus is that it would be necessary to act on almost 100% of the viral reservoir (approximately 1,000,000 cells). The study has also been designed to enable us to understand the biochemical and molecular mechanisms by which certain drugs can induce viral reactivation in vitro as a previous step to a clinical trial aimed at reactivating viral latency and eradicating HIV-1 from the body. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Basic Science | |||
Condition ICMJE | HIV-1 | |||
Intervention ICMJE | Drug: maraviroc
Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours. Other Names:
| |||
Study Arms ICMJE | Experimental: Maraviroc
Adult patients with HIV infection and a viral load that has been suppressed for a long period (less than 50 copies/mL for at least 2 years) while on antiretroviral therapy.The treatment group will maintain the habitual antiretroviral therapy combined with maraviroc. Intervention: Drug: maraviroc | |||
Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 10 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | January 2015 | |||
Actual Primary Completion Date | January 2015 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Spain | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00795444 | |||
Other Study ID Numbers ICMJE | ERRADVIH-01 Eudra CT 2007-003995-21 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | |||
Study Sponsor ICMJE | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | |||
Verification Date | January 2015 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |